Skip to main content
Smart Investors Daily
Zoetis Inc. logo

NASDAQ · ZTS

Zoetis Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$80.79

Down-$4.78 (-5.59%)

Updated Nov 20, 2026, 2:25 AM

SID Score

6.1/10

Composite research score

Smart Money

56/100

Neutral

Market cap
51.85B
P/E ratio
19.66
Dividend yield
2.48%
52-week range
$68.77 – $132.49
Volume
4.71M
Avg. volume
4.62M

Price performance · ZTS

ZTS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

ZTS closed at $80.79 after 21 trading sessions, down 1.48% for the selected period.

Last close
$80.79
Period change
-1.48%
Period low
$77.80
Period high
$89.20
Daily close
View OHLC price history
ZTS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$84.84$85.13$80.71$80.794.71M
Nov 18, 2026$82.15$86.58$82.15$85.574.66M
Nov 17, 2026$84.045$85.56$83.05$83.483.4M
Nov 16, 2026$84.26$84.57$83.175$84.394.09M
Nov 13, 2026$83.50$83.85$82.265$83.823.15M
Nov 12, 2026$82.69$83.84$82.48$82.964.39M
Nov 11, 2026$81.49$82.64$80.79$82.574.45M
Nov 10, 2026$81.75$83.28$80.43$82.464.89M
Nov 9, 2026$80.45$82.5987$79.59$82.326.21M
Nov 6, 2026$79.00$80.67$78.63$79.406.02M
Nov 5, 2026$84.87$88.74$81.54$82.1110.09M
Nov 4, 2026$85.37$89.29$84.83$89.209.18M
Nov 3, 2026$82.29$83.73$81.526$82.993.73M
Nov 2, 2026$80.15$83.225$79.8901$83.185.42M
Oct 30, 2026$79.84$80.605$79.215$79.724.12M
Oct 29, 2026$78.44$79.2805$77.76$78.802.94M
Oct 28, 2026$77.355$78.555$77.03$77.802.62M
Oct 27, 2026$80.59$80.59$78.065$78.232.83M
Oct 26, 2026$80.95$81.19$80.10$80.972.9M
Oct 23, 2026$81.14$81.86$80.6001$81.032.86M
Oct 22, 2026$79.90$82.29$79.90$82.004.83M

Latest ZTS news

The latest Smart Investors Daily articles mentioning ZTS.

ZTS research

Overview

Company profile and research snapshot.

Company profile

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$157.80
Implied upside
—
Analysts
17
ZTS recent ratings
DateFirmRatingTarget
Oct 29, 2026Morgan StanleyOverweight—
Oct 27, 2026UBSNeutral—
Oct 20, 2026JefferiesHold—
Oct 16, 2026Goldman SachsNeutral—
Aug 25, 2026TD CowenBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

Zoetis to Participate in the Jefferies Global Healthcare Conference in London

PARSIPPANY, N.J., November 10, 2026--Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 2 p.m. GMT.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.